Abstracts tagged "Bone"

Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Chad Deal¹, Bruce Mitlak², Yamei Wang², Lorraine A Fitzpatrick² and Paul D Miller³, ¹Cleveland Clinic, Shaker Heights, OH, ²Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…
Abstract Number: 57 • 2018 ACR/ARHP Annual Meeting
Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model
Dale Wright, Ben Zweifel, Steve Settle and Rick Fitch, Pharmacology, Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Repository corticotropin injection (RCI: H.P. Acthar® gel) contains a purified porcine pituitary ACTH-analogue, and is an FDA-approved treatment for short-term adjunctive therapy of acute…
Abstract Number: 2308 • 2018 ACR/ARHP Annual Meeting
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
Jean Yves Reginster¹, Florence Bianic², Rosanne Campbell², Monique Martin², Setareh A. Williams³ and Lorraine A Fitzpatrick³, ¹Université de Liège, Liège, Belgium, ²inVentiv Health, London, United Kingdom, ³Radius Health, Inc., Waltham, MA
Background/Purpose: To assess the relative efficacy of abaloparatide compared with other osteoporosis treatment options (alendronate, denosumab, ibandronate, raloxifene, risedronate, romosozumab, strontium ranelate, teriparatide, zoledronic acid).…
Abstract Number: 308 • 2018 ACR/ARHP Annual Meeting
Carpal Bones Affectation Frequency in Rheumatoid Arthritis By Magnetic Resonance Imaging
Maria Del Carmen Larios-Forte¹, Cassandra Skinner-Taylor¹, Dionicio A. Galarza-Delgado², Jorge Esquivel-Valerio³, Janett Riega-Torres⁴, David Vega-Morales¹ and Itzel Perez-Onofre⁵, ¹Rheumatology, University Hospital “Dr. José Eleuterio González”, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, University Hospital “Dr. José Eleuterio González”, UANL, Mexico, Monterrey, Mexico, ⁴University Hospital “Dr. José Eleuterio González”, UANL, Monterrey, Mexico, ⁵Rheumatology, University Hospital “Dr. José Eleuterio González” U.A.N.L, Monterrey, Mexico
Background/Purpose: Wrist joint between radio-ulna and first carpal row; scaphoid and triquetrum bones stabilize the central carpal column and support the flexion-extension or abduction-adduction movements1.…
Abstract Number: 2335 • 2018 ACR/ARHP Annual Meeting
Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees: 2007-2017
E. Michael Lewiecki¹, Benjamin Chastek², Kevin Sundquist², Setareh A. Williams³, Deane Leader Jr.³, Richard Weiss³, Yamei Wang³, Lorraine A Fitzpatrick³ and Jeffrey R. Curtis⁴, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Optum, Eden Prairie, MN, ³Radius Health, Inc., Waltham, MA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoporosis-related fractures (fractures) are a leading cause of morbidity and disability in the US. Epidemiological data on the occurrence of fractures are limited and…
Abstract Number: 865 • 2018 ACR/ARHP Annual Meeting
Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study
Dongze Wu¹, James F Griffith², Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Lin Shi³, Edmund Li¹, Isaac T. Cheng¹, Tena K. Li¹, Tracy Y. Zhu⁴, Vivian W. Hung⁴, Ling Qin⁵ and Lai-Shan Tam⁶, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Research Centre for Medical Image Computing, Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁵Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Metacarpal head directly exposed to intra-articular inflammatory milieu, therefore may lead to abnormal bone remodeling (bone loss and new bone formation). The aims of…
Abstract Number: 2730 • 2018 ACR/ARHP Annual Meeting
Handgrip Strength Predicts the Risk of Bone Fracture and Severe Adverse Events in Patients with Systemic Necrotizing Vasculitis
Soledad Henriquez¹, Bertrand Dunogué², Raphaël Porcher³, Alexis Régent¹, Pascal Cohen⁴, Alice Bérezné¹, Sami Kolta⁵, Claire Le Jeunne¹, Luc Mouthon⁶, Christian Roux⁵, Loïc Guillevin⁷, Karine Briot⁸ and Benjamin Terrier⁹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Internal Medicine, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes Sorbonne Paris, Paris, France, ⁴Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁵Department of Rheumatology, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ⁷Medecine Interne, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Department of Rheumatology, Cochin Hospital and Epidemiology and Biostatistics Unit,Sorbonne Paris Cité Reserach Center,Paris Descartes University,INSERM U1153, Paris, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Sarcopenia, characterized by progressive loss of both muscle mass and muscle strength, has been associated with poor outcomes in various diseases. Muscle weakness is…
Abstract Number: 1044 • 2018 ACR/ARHP Annual Meeting
Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model
Ane Larrañaga Vera¹, Kiran Toti², Eugene Warnick², Harsha Rao², Zhan-Guo Gao², Alexandra Gadiano², Aranzazu Mediero³, Kenneth A. Jacobson² and Bruce N. Cronstein⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²Molecular Recognition Section, NIDDK-NIH, Bethesda, MD, ³Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ⁴Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: The most common cause of total joint replacement revision surgeries is loosening of the implant due to loss of bone around the prosthesis. Wear…
Abstract Number: 2810 • 2018 ACR/ARHP Annual Meeting
Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
Benjamin Leder¹, Carol Zapalowski², Ming-Yi Hu³ and Gary Hattersley², ¹Endocrine, Harvard Medical School, Boston, MA, ²Radius Health, Inc., Waltham, MA, ³Biometrics, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide (ABL) is an anabolic PTHrP analog approved to treat postmenopausal women with osteoporosis at high risk of fracture. In the ACTIVE Phase 3…
Abstract Number: 1067 • 2018 ACR/ARHP Annual Meeting
Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model
Alexandra Damerau^1,2, Annemarie Lang^1,2, Moritz Pfeiffenberger^1,2, Timo Gaber^1,3 and Frank Buttgereit^1,2, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ³Deutsches Rheuma Forschungszentrum (DRFZ) Berlin, Berlin, Germany
Background/Purpose: Although arthritis is a matter of research since more than 140 years, there is currently no valid 3D model available, which is able to…
Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Susan L. Greenspan¹, Lorraine A Fitzpatrick², Bruce Mitlak², Yamei Wang², Nicholas C. Harvey³, Chad Deal⁴, Felicia Cosman⁵ and Michael McClung⁶, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Radius Health, Inc., Waltham, MA, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Cleveland Clinic, Shaker Heights, OH, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Oregon Osteoporosis Center, Portland, OR
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…
Abstract Number: 1197 • 2018 ACR/ARHP Annual Meeting
The Characteristics of the Distribution of Normal Feeding Vessels between Young and Elderly Adults in Wrist Joints of Healthy Volunteers Depicted By Ultrasound (MSKUS)
Kenta Misaki¹, Kei Ikeda², Kenshi Inoue³, Moemi Miyazaki³, Naofumi Dobashi³ and Yasuhiko Imaizumi⁴, ¹Rheumatology, Kita-Harima Medical Center, Ono, Japan, ²Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ³Kita-Harima Medical Center, Ono, Japan, ⁴kita-Harima Medical Center, Ono, Japan
Background/Purpose: Synovial vascularity as measured by power Doppler (PD) of MSKUS is correlated to rheumatoid arthritis disease activity, and PD signal reveals the prevalence of…
Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting
Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture
Mariana O Perez¹, Diogo S Domiciano¹, Luciene M Reis², Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
Abstract Number: 1481 • 2018 ACR/ARHP Annual Meeting
Are ACPA Associated with More Bone Loss over Time in Patients with RA?
Emma de Moel¹, Josephine Amkreutz¹, Lotte Heimans², Cornelia F. Allaart³, Tom W.J. Huizinga⁴ and Diane van der Woude⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are one of the most important serological markers for rheumatoid arthritis (RA) and have been suggested to play a pathophysiologic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].